Daratumumab subcutaneous-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen1
Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity
BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (“Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023. The Reverse Stock Split, which was approved by stockholders at the Company’s Special Meeting of Stockholders on December 8, 2023, is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. Beginning with the opening of trading on Monday, December 18, 2023, the Company’s common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the existing symbol “CYCC” and a new CUSIP number 23254L801.
Excerpt from:
Cyclacel Pharmaceuticals Announces Reverse Stock Split
HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:?HCM, HKEX:?13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.
Go here to read the rest:
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:?HCM, HKEX:?13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) at the same terms as the current two-year agreement.
See the original post:
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at...
Initial development in PIDs with immune dysregulation linked to PI3K? signaling
Continue reading here:
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis’. Novonesis means ‘A new beginning’ and derives from the Greek word ‘genesis’. The name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.
See the original post:
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
ROCHESTER, Minn. A multinational clinical trial involving Mayo Clinic researchers has found stem cell-based therapy improved quality of life for patients with advanced heart failure.
In the study, patients reported their daily hardship lessened when stem cells optimized for heart repair supplemented the standard of care, and the study further documented lower death and hospitalization rates among those treated with cell therapy.
"In this era of global aging, people live longer, yet are at risk of chronic disease imposing a poor quality of life. Heart failure is an emerging epidemic in need of new healing options," says Andre Terzic, M.D., Ph.D., a Mayo Clinic cardiovascular researcher and lead author of the paper. "The stem cell-based approach in the present study demonstrates sustained benefit on physical and emotional health in response to biotherapy."
Dr. Terzic is the Marriott Family Director, Comprehensive Cardiac Regenerative Medicine for the Center for Regenerative Biotherapeutics.
Approximately 800,000 people in the U.S. suffer heart attacks every year.
The study team recruited 315 patients from 39 hospitals in 10 countries who had advanced heart failure despite receiving standard of care. Mayo Clinic says patients were randomly divided into groups that would receive stem cell therapy versus those who would not. Patients assigned to cell treatment underwent cardiac catheterization. Then, stem cells taken from their own bone marrow and programmed to heal damaged heart tissue were delivered to the heart. Patients assigned not to receive stem cells had cardiac catheterization without cell delivery known as the sham treatment.
"Data from one of the largest cardiovascular cell therapy trials, testing a regenerative technology discovered at Mayo Clinic, indicate benefit in both quantity and quality of life in advanced heart disease," saysSatsuki Yamada, M.D., Ph.D., a Mayo Clinic cardiovascular researcher, and first author on the study. "The benefit of regenerative care has been typically evaluated on the basis of clinician-reported outcomes. What's unique in this study is that it was designed to listen to the patient's experience."
This research is published in Stem Cells Translational Medicine.
See the article here:
Mayo Clinic researchers say stem cell therapy improves quality of life for patients with advanced heart failure - WXOW.com
CHICAGO, Dec. 12, 2023 /PRNewswire/ --Stem Cell Therapy Marketin terms of revenue was estimated to be worth $286 million in 2023 and is poised to reach $615 million by 2028, growing at a CAGR of 16.5% from 2023 to 2028 according to a new report by MarketsandMarkets. The global stem cell therapy market is expected to grow at a CAGR of 16.8% during the forecast period. The major factors driving the growth of the market are expanding number of clinical trials of stem cell therapies, rise in stem cell research funding and growing number of GMP-certified cell therapy production facilities. However, high costs associated with the development of stem cell therapy and treatment is anticipated to hamper the market growth in coming years.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48
Browse in-depth TOC on "Stem Cell Therapy Market"
157 - Tables
40 - Figures
203 - Pages
Stem Cell Therapy Market Scope:
Report Coverage
Details
Market Revenue in 2023
$286 million
Estimated Value by 2028
$615 million
Growth Rate
Poised to grow at a CAGR of 16.5%
Market Size Available for
2021-2028
Forecast Period
2023-2028
Forecast Units
Value (USD Million)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Cell Source, Type, Therapeutic Application and Region
Geographies Covered
North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
The emergence of iPSCs as an alternative to ESCs
Key Market Drivers
Increased funding for stem cell research
The adipose tissue derived MSCs segment dominated the stem cell therapy market in 2022.
The global stem cell therapy market is segmented into adipose tissue-derivedMSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Prominent factors such as easy availability of adipose-derived stem cell tissues and its diversified properties properties similar to other mesenchymal stem cells/tissues is likely to uplift the demand for adipose tissue derived MCs.
In 2022, the musculoskeletal disorders led the stem cell therapy market.
Based on therapeutic application, the global stem cell therapy market is segmented intomusculoskeletal disorders, wounds & surgeries, cardiovascular diseases, surgeries, inflammatory & autoimmune diseases, neurological disorders, and other therapeutic applications. The large share of this segment can be attributed increasing prevalence of musculoskeletal diseases. Increasing investment in stem cell therapy for neurological diseases is likely to skyrocket the segment in coming years.
The Asia Pacific region is likely to grow at faster pace during the forecast period.
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the stem cell therapy markets in the region is driven by a rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of stem cell therapies among the patient population. The rising prevalence of cancer and increased investment in research & development of the launch of novel stem cell therapies in the region are some of the major factors anticipated to upsurge the market growth.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=48
Stem Cell Therapy MarketDynamics:
Drivers:
1. Increased funding for stem cell research
Restraints:
1. Ethical concerns related to embryonic stem cells
Opportunities:
1. The emergence of iPSCs as an alternative to ESCs
Challenge:
1. Technical limitations
Key Market Players ofStem Cell Therapy Industry:
The stem cell therapy market is competitive, with a small number of players competing for market shares. Smith+Nephew (UK),MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), CORESTEM (South Korea), Pharmicell Co., Ltd. (South Korea), NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Holostem Terapie Avanzate Srl (Italy), Orthofix (US), Regrow Biosciences Pvt Ltd. (India), and STEMPEUTICS RESEARCH PVT LTD. (India) among others are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
The primary interviews conducted for this report can be categorized as follows:
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=48
Stem Cell Therapy Market Recent Developments:
Stem Cell Therapy Market - Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and itssubsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Related Reports:
Stem Cell Assays Market- Global Forecasts to 2027
Biologics Safety Testing Market- Global Forecasts to 2027
Nerve Repair & Regeneration Market- Global Forecasts to 2027
Bone Growth Stimulator Market- Global Forecasts to 2027
Mycoplasma Testing Market- Global Forecasts to 2025
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping themmonetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. TheKnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visitwww.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish Mehra MarketsandMarkets INC. 2860 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/stem-cell-technologies-and-global-market.asp Visit Our Website: https://www.marketsandmarkets.com/ Content Source: https://www.marketsandmarkets.com/PressReleases/stem-cells-market.asp
Logo: https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg
SOURCE MarketsandMarkets
See original here:
Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets - PR Newswire
Researchers have developed a wayto generate a family of nerve cells implicated in Parkinsons disease in the lab using human stem cells, according to newly published research.
These cells, found in a brain region called the locus coeruleus (LC), produce a signaling chemical called norepinephrine, or NE. While these cells are known to degenerate early in Parkinsons and other neurological diseases, it is not known exactly why.
The scientists discovered a protein important for the cells growth, which enabled them to be generated in the lab. The team now plans to use the stem cell model to more closely study neurodegenerative disease mechanisms and to test possible therapeutic candidates.
Importantly, according to Yunlong Tao, PhD, the studys first author, we have some new understanding about locus coeruleusdevelopment.
Thats the major finding in this paper, and based on that finding, we are able to generate locus coeruleus norepinephrine neurons, Tao said in a press release from the University of Wisconsin (UW)-Madison, where the study was conducted. Tao, an investigator at Nanjing University, in China, was working as a UW-Madison researcher at the time of the study.
Titled Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells, the study was published in Nature Biotechnology.
A tiny cluster of nerve cells (neurons) deep in the brain, the locus coeruleus plays a critical role in brain function. The cells there are the main producers of norepinephrine, a signaling chemical best known for its role in mediating so-called fight or flight reactions that occur during stressful situations.
Nerve cells originating in the locus coeruleus extend throughout the brain and spinal cord via an extensive branching system, where they release norepinephrine to regulate heartbeat, blood pressure, arousal, memory, and attention.
The norepinephrine neurons in the locus coeruleus are essential for our life, said Su-Chun Zhang, MD, PhD, a neuroscience and neurology professor at UW-Madison and the studys senior author.
We call it the life center, Zhang said, adding that without these nerve cells, we would probably be extinct from Earth.
Dysfunction of this brain region, therefore, can have severe consequences for brain health. Indeed, locus coeruleus-norepinephrine (LC-NE) cells have been implicated in a range of neurodegenerative diseases, including Parkinsons and Alzheimers disease.
In Parkinsons, the locus coeruleus is one of the first brain regions to start degenerating. This has been associated with a range of the diseases nonmotor symptoms.
People have noticed this for a long time, but they dont know what the function of the locus coeruleus is in this process, Tao said, adding thats also partly because we dont have a good model to mimic the human LC-NE neurons.
Stem cells, which have the capacity to become virtually any other cell type under the right conditions, give rise to basically all mature cells in the body. Scientists can leverage this to generate nerve cells of human origin in the lab. When treated with specific chemicals, stem cells can be prompted to turn into almost any cell type the researchers want to study.
However, this has proven difficult in the past with LC-NE neurons, and several attempts had failed.
In their new study, the team identified that a growth factor protein called ACTIVIN-A is necessary for regulating the development of these cells. Without it, the gene activity needed for precursor cells to become LC-NE neurons cant occur.
By adding in ACTIVIN-A during the process, the scientists could thus develop LC-NE neurons from stem cells. The cells they produced had the expected structural and functional characteristics of LC-NE neurons, including the release of NE and other functions related to their role in breathing and heart rate.
Ultimately, the researchers believe the LC-NE cells can be used to further study how and why these cells seem to die off so early in diseases like Parkinsons.
If this is somewhat causative, then we could potentially do something to prevent or delay the neurodegeneration process, Zhang said.
The availability of functional human LC-NE neurons enables investigation of their roles in psychiatric and neurodegenerative diseases and provides a tool for therapeutics development.
Stem cell-derived neurons will have the genetic and cellular characteristics of the person from whom the stem cells were taken. As such, scientists could generate LC-NE neurons from Parkinsons patients to learn more about how the cells behave and how they respond to therapeutic candidates.
The availability of functional human LC-NE neurons enables investigation of their roles in psychiatric and neurodegenerative diseases and provides a tool for therapeutics development, the researchers wrote.
The team also developed a line of the cells with a fluorescent sensor for detecting norepinephrine levels, which the scientists believe, may be useful to find novel drugs that regulate NE [norepinephrine] release and/or uptake.
As a next step, the scientists plan to look more closely at how ACTIVIN-A regulates LC-NE cell development. In addition, the team will use the stem cell model for experiments aimed at modeling human disease and testing therapeutics.
The application of these cells is quite broad in its significance, Zhang noted.
Link:
Lab-made stem cell model will offer new way to study Parkinson's - Parkinson's News Today
